Transactions in relation to share buyback program

Udgivet den 31-10-2017  |  kl. 11:53  |  

Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on market abuse and the delegated regulation (EU) no. 2016/1052 of 8 March 2016, also referred to as the Safe Harbor rules (company announcement no. 20 of May 4, 2017). 

The share buyback program has been initiated in order to reduce the company's share capital and to cover obligations under the long-term incentive program. Under the share buyback program, which is running from May 4, 2017 and ending no later than March 12, 2018, GN intends to buy back shares for an amount of up to DKK 1,000 million. 

The following transactions have been made under the program in the period October 24, 2017 - October 30, 2017:

  

  No. of shares Average purchase price, DKK Transaction Value, DKK
October 24, 2017 20,000 202.75 4,055,096
October 25, 2017 10,000 203.47 2,034,686
October 26, 2017 10,000 202.58 2,025,766
October 27, 2017 0 0.00 0
October 30, 2017 10,000 208.56 2,085,551
Accumulated under the program 2,468,099 200.42 494,647,955

Following the above transactions GN owns a total of 8,400,315 own shares corresponding to 5.8% of the company's total share capital. Every Tuesday, GN will announce the number and value of repurchased shares in company announcements to Nasdaq Copenhagen. 

For further information, please contact:

Investors and analysts
Peter Justesen
VP - Investor Relations & TreasuryT
el: +45 45 75 87 16

Press and the media
Lars Otto Andersen-Lange
Group Media Manager
Tel: +45 45 75 02 55

About GN Group
GN Group is a global leader in intelligent audio solutions that let you hear more, do more and be more than you ever thought possible. We transform lives through the power of sound: Smart Hearing aids that enhance the lives of people with hearing loss; integrated headset and communications solutions that assist professionals in all types of businesses to be more productive; wireless headsets and earbuds designed to support any lifestyle - from sports enthusiasts to commuters and office workers.  

With world leading expertise in the human ear, sound, wireless technology and miniaturization, GN's innovative and intelligent audio solutions are marketed by the brands Jabra, ReSound, Beltone and Interton in 100 countries across the world. Founded in 1869, the GN Group today has more than 5,000 employees and is listed on Nasdaq Copenhagen (GN.CO). 

Visit our homepage GN.com - and connect with us on LinkedIn, Facebook and Twitter.

Vedhæftede filer:

Announcement 54 - Transactions under share buyback program.pdf

GN_STORE.pdf

Udgivet af: NPinvestordk

Seneste nyheder

17:49 Europa/lukning: Danske fedmeaktier blødte og trak Europa i rødt
17:19 Fredagens obligationer: Renter faldt efter amerikanske inflationstal
17:18 Novo banket i bund efter skuffende data - aktionærerne tabte omkring 690 mia. kr.
17:06 Fredagens aktier: Øretæver til Novo Nordisk og Zealand Pharma giver solid C25-nedtur
15:46 USA/åbning: Eli Lilly vinder på Novos kollaps mens inflationsdata skærer lidt af dykket
15:17 Jeudan har milliarder klar til opkøb: "Øget optimisme kan give flere transaktioner i 2025"
15:15 Novo/Jyske Bank: Kursreaktion virker som overreaktion
14:29 USA/tendens: Eli Lilly vinder på Novos kollaps mens frygt for nedlukning varsler rød start
13:33 Korr: Udsalg af Novo-aktier presser kronen
13:24 Udsalg af Novo-aktier presser kronen
12:29 Sydbank-analytiker: Voldsomt kursfald afspejler skuffelsen over Cagrisema-data
12:25 Europa/aktier: Danske fedmeaktier bløder og trækker Europa i rødt
12:22 Novo smadres på børsen efter skuffende fedmestudie - aktien taber 770 mia. kr.
12:11 Novos styrtdyk trækker C25-indekset ned i sit fjerdestørste fald nogensinde
12:09 Gubra og Zealand Pharma trækkes med ned af negativt nyt til Novo Nordisk
12:05 Novo lever ikke op til egne forventninger i vigtigt studie - aktien mister 900 mia kr -NY2
11:56 Novo lever ikke op til egne forventninger i kursfølsomt studie - aktien mister 700 mia kr
11:48 Aktier/middag: Zealand Pharma bankes tocifret ned efter FDA-afvisning og trækker C25 ned
11:28 Obligationer/middag: Små renteudsving før inflationsnyt fra USA
10:49 Jefferies ser kurslussing til Zealand Pharma som købsmulighed